Wide Ranks

CORT

Corcept Therapeutics Incorporat

58.60

Top Statistics
Market Cap 6 B Forward PE 33.49 Revenue Growth 47.70 %
Current Ratio 3.70 Trailing PE 46.51 Earnings Growth 46.40 %
Profit Margins 22.56 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 40.02 Enterprise / Revenue 9.17 Price To Sales Trailing12 Months 9.77
Profitability
Profit Margins 22.56 % Operating Margins 25.53 %
Balance Sheet
Total Cash 380 M Total Cash Per Share 3.63 Total Debt 6 M
Total Debt To Equity 1.06 Current Ratio 3.70 Book Value Per Share 6.10
All Measures
Short Ratio 1507.00 % Message Board Id finmb_1423826 Shares Short Prior Month 20 M
Return On Equity 0.2577 City Menlo Park Uuid a461c3f8-0bad-368f-8e34-11b913003b11
Previous Close 58.58 First Trade Date Epoch Utc 1 B Book Value 6.10
Beta 0.4550 Total Debt 6 M Volume 465963
Price To Book 9.60 Fifty Two Week Low 20.84 Total Cash Per Share 3.63
Total Revenue 628 M Shares Short Previous Month Date 1 B Target Median Price 76.00
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins 25.53 %
Target Mean Price 74.90 Net Income To Common 140 M Short Percent Of Float 0.2458
Implied Shares Outstanding 104 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 869560 Average Volume10days 869560 Total Cash 380 M
Next Fiscal Year End 1 B Revenue Per Share 6.11 Held Percent Insiders 0.1152
Ebitda Margins 22.92 % Trailing PE 46.51 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 58.58 Target Low Price 67.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 49.52 Open 58.86
Free Cashflow 140 M State CA Dividend Yield 0.00 %
Return On Assets 0.1300 Time Zone Short Name EST Trailing Eps 1.26
Day Low 57.87 Address1 149 Commonwealth Drive Shares Outstanding 104 M
Price Hint 2 Target High Price 80.00 Website https://www.corcept.com
52 Week Change 1.30 Average Volume 980343 Earnings Quarterly Growth 50.50 %
Forward Eps 1.75 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 350.90 % Is_sp_500 False Regular Market Day High 59.21
Profit Margins 22.56 % Debt To Equity 1.06 Fifty Two Week High 61.66
Day High 59.21 Shares Short 18 M Regular Market Open 58.86
Industry Key biotechnology Earnings Growth 46.40 % Enterprise To Revenue 9.17
Revenue Growth 47.70 % Shares Percent Shares Out 0.1751 Operating Cashflow 144 M
Currency USD Time Zone Full Name America/New_York Market Cap 6 B
Is_nasdaq_100 False Zip 94025 Quote Type EQUITY
Industry Biotechnology Long Name Corcept Therapeutics Incorporated Regular Market Day Low 57.87
Held Percent Institutions 0.8551 Current Price 58.60 Enterprise To Ebitda 40.02
Financial Currency USD Current Ratio 3.70 Gross Margins 98.44 %
Industry Disp Biotechnology Number Of Analyst Opinions 5 Country United States
Float Shares 85 M Two Hundred Day Average 34.34 Enterprise Value 5 B
Price To Sales Trailing12 Months 9.77 Forward PE 33.49 Regular Market Volume 465963
Ebitda 144 M Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors.

In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial.

The company was incorporated in 1998 and is headquartered in Menlo Park, California.